Diverse quality of copycats and public risk

When pharmaceutical giant Novo Nordisk developed a new medication for type 2 diabetes, they noticed that a welcome side effect was a small amount of weight loss. They had no idea that their new diabetes medication was about to become a multibillion-dollar weight loss drug. But they had no sooner launched this game-changing drug, then competitors swooped in to knock Novo Nordisk off its throne.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.